J Cancer 2018; 9(10):1773-1781. doi:10.7150/jca.24577 This issue


Current status and future directions of cancer immunotherapy

Hongming Zhang, Jibei Chen

Department of Respiratory Medicine, Yancheng Third People's Hospital, the Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng, Jiangsu, China.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer 2018; 9(10):1773-1781. doi:10.7150/jca.24577. Available from https://www.jcancer.org/v09p1773.htm

File import instruction


In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Recent years' success of cancer immunotherapy including monoclonal antibodies (mAbs), cancer vaccines, adoptive cancer therapy and the immune checkpoint therapy has revolutionized traditional cancer treatment. However, challenges still exist in this field. Personalized combination therapies via new techniques will be the next promising strategies for the future cancer treatment direction.

Keywords: cancer, immune system, cancer immunotherapy, challenges, future directions